Eli Lilly announced a partnership for a digital patient care solution with Senderra, though market dynamics caused stock issues.
2 reports, 2 independent
Updated Aug 10
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Eli Lilly announced a partnership for a digital patient care solution with Senderra, though market dynamics caused stock issues.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
Related events
- Eli Lilly and Company entered a strategic partnership with Twist Bioscience Corporation regarding data provision and services.
- Eli Lilly and Novo Nordisk are pushing for claims-level patient data submission.
- Eli Lilly and Peptron evaluated technology partnership approaches related to national health insurance policy.
- Eli Lilly announced multiple new partnerships, including expanding Zepbound access with CVS Health, collaborating with Insilico Medicine, and investing in an AI lab with NVIDIA.
Coverage
Newest first; wire copies grouped- Simply Wall St.Eli Lilly (LLY) Partners With Senderra For Innovative Digital Patient Care Solution Eli Lilly recently introduced EBGLYSS through Senderra Specialty Pharmacy, targeting patients with atopic dermatiti
- PR NewswireElevating Patient Care: Senderra Specialty Pharmacy Adds EBGLYSS™ (lebrikizumab-lbkz), Lilly's First-Line Biologic Treatment for Moderate-to-Severe Atopic Dermatitis, to SenderraCare+ for a Streamline